BCL6 and lymphoma: The in vitro TR-FRET assay proved instrumental in the optimisation of biochemical potency and the InCell Hunter and NanoBRET assays were crucial in assessing the cellular activity of the compounds, thus aiding the discovery of a series of potent benzimidazolone- and quinolinone-based BCL6 inhibitors showing sub-micromolar cellular activity and antiproliferative effect in the BCL6-dependent lymphoma cell lines OCI-LY1 and SU-DH-L415,40.